Wilson, M.-M.; Henshall,D.C.; Byrne, S.M.; Brennan, G.P.CHD2-Related CNS Pathologies.Int.J. Mol. Sci.2021,22, 588. https://doi.org/10.3390/
Abstract:
Epileptic encephalopathies (EE) are severe epilepsy
syndromes characterized by multiple seizure types, developmental delay and even
regression. This class of disorders are
increasingly being identified as resulting from de novo genetic mutations
including many identified mutations in the family of chromodomain helicase DNA
binding (CHD) proteins. In particular,
several de novo pathogenic mutations have been identified in the gene encoding
chromodomain helicase DNA binding protein 2 (CHD2), a member of the sucrose
nonfermenting (SNF-2) protein family of epigenetic regulators. These mutations
in the CHD2 gene are causative of early onset epileptic encephalopathy, abnormal
brain function, and intellectual disability.
Our understanding of theme chanisms by which modification or loss of CHD2
cause this condition remains poorly understood. Here, we review what is known
and still to be elucidated as regards the structure and function ofCHD2 and how
its dysregulation leads to a highly variable range of phenotypic presentations.
Courtesy of Researchgate
No comments:
Post a Comment